- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05155345
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus
April 5, 2024 updated by: Hoffmann-La Roche
A Phase Ib, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus
This study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of mosunetuzumab in participants with systemic lupus erythematosus (SLE).
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
50
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Reference Study ID Number: GA43191 https://forpatients.roche.com/
- Phone Number: 888-662-6728
- Email: global-roche-genentech-trials@gene.com
Study Locations
-
-
-
Tbilisi, Georgia, 0112
- Active, not recruiting
- LLC Arensia Exploratory Medicine
-
-
-
-
-
Chisinau, Moldova, Republic of, MD-2025
- Completed
- ICS ARENSIA Exploratory Medicine
-
-
-
-
-
Bydgoszcz, Poland, 85-168
- Recruiting
- Szpital Uniwersytecki nr 2 im. Dr Jana Biziela w Bydgoszczy
-
Poznan, Poland, 61-545
- Recruiting
- Ortopedyczno Rehab Szpital Klinic im Wiktora Degi UM; Oddzial Reumat Rehab i Chorob Wewnetrznych
-
-
-
-
KIEV Governorate
-
Kyiv, KIEV Governorate, Ukraine, 01135
- Withdrawn
- Medical Center of Limited Liability Company ?Harmoniya krasy?
-
-
-
-
Alabama
-
Anniston, Alabama, United States, 36207
- Recruiting
- Pinnacle Research Group; Llc, Central
-
-
New York
-
Syracuse, New York, United States, 13210
- Recruiting
- SUNY Upstate Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria at least 12 weeks or more prior to screening
- Presence of one or more of the following SLE autoantibodies documented within the 12 months prior to screening or during screening: positive ANA (greater than or equal to 1:160); anti dsDNA above the upper limit of normal (ULN); anti-Sm above the ULN
- Active SLE disease, as demonstrated by a SLEDAI-2K total score of greater than or equal to 4 at screening
- Current receipt of one or more of the following classes of standard therapies for the treatment of SLE at stable doses: oral corticosteroids (OCSs), antimalarial agents, conventional immunosuppressants
- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraception as defined by the protocol
- For men on mycophenolate mofetil (MMF): With a female partner of childbearing potential, men who are not surgically sterile must remain abstinent (refrain from heterosexual intercourse) or use contraception as defined by the protocol
Exclusion Criteria:
- Pregnant or breastfeeding, or intending to become pregnant during the study or within 3 months after the final dose of mosunetuzumab and 3 months after the final dose of tocilizumab
- Active severe or unstable lupus-associated neuropsychiatric disease that is likely to require treatment with protocol-prohibited therapies
- Active overlap syndrome with mixed connective tissue disease or systemic sclerosis within 12 months prior to screening or during screening
- Catastrophic or severe antiphospholipid syndrome within 12 months prior to screening or during screening
- Presence of significant lupus-associated renal disease and/or renal impairment that is likely to require treatment with protocol-prohibited therapies
- Peripheral CD19+ B-cell count < 25 cells/uL
- Receipt of an investigational therapy within 30 days or 5 drug-elimination half-lives (whichever is longer) prior to initiation of study treatment and during the study
- Receipt of any of the following excluded therapies: any anti-CD19 or anti-CD20 therapy such as blinatumomab, obinutuzumab, rituxumab, ocrelizumab, or ofatumumab less than 12 months prior to screening or during screening; inhibitors of JAK, Bruton tyrosine kinase, or tyrosine kinase 2, including baricitinib, tofacitinib, upadacitinib, filgotinib, ibrutinib, or fenebrutinib, or any investigational agent within 30 days prior to screening or during screening; tacrolimus, ciclosporin, or voclosporin within 30 day prior to screening or during screening; cyclophosphamide or a biologic therapy such as but not limited to belimumab, ustekinumab, anifrolumab, secukinumab, or atacicept during 2 months prior to screening or during screening; any live or attenuated vaccine during 28 days prior to screening or during screening
- High risk for any clinically significant bleeding or any condition requiring plasmapheresis, IV immunoglobulin, or acute blood product transfusions
- Significant or uncontrolled medical disease that would preclude participation
- HIV infection, acute or chronic hepatitis B virus (HBV), acute or chronic hepatitis C (HCV) infection, tuberculosis (TB) infection, known or suspected chronic active Epstein-Barr virus (EBV) infection, or cytomegalovirus (CMV) infection
- Active infection of any kind, excluding fungal infection of the nail beds
- Any major episode of infection that fulfills any of the following criteria: requires hospitalization during 8 weeks prior to screening or during screening; requires treatment with IV antibiotics (or anti-infective medications) during 8 weeks prior to screening or during screening; requires treatment with oral antibiotics (or anti-infective medications) during 2 weeks prior to screening or during screening
- History of serious recurrent or chronic infection
- History of progressive multifocal leukoencephalopathy (PML)
- History of cancer, including solid tumors, hematological malignancies, and carcinoma in situ, within the past 5 years
- Major surgery requiring hospitalization during 4 weeks prior to screening or during screening or any planned surgery or procedure requiring hospitalization during 12 weeks following study drug administration
- Current alcohol or drug abuse or history of alcohol or drug abuse within 12 months prior to screening or during screening
- Intolerance or contraindication to study therapies including history of severe allergic or anaphylactic reactions to monoclonal antibodies or known hypersensitivity to any component of mosunetuzumab injection
- Positive serum human chorionic gonadotropin measures at screening
- Any of the following laboratory parameters: aspartate transaminase (AST) or alanine transaminase (ALT) > 2.5 x upper limit of normal (ULN); total bilirubin > 1.5 x ULN; absolute neutrophil count (ANC) < 2.0 x 10^9/L (< 2000/mm^3); platelet count < 100 x 10^9/L (100,000 mm^3); hemoglobin < 100 g/L (10 g/dL); estimated glomerular filtration rate (eGFR) < 30 ml/min/1.73 m^2 calculated according to the Chronic Kidney Disease Epidemiology Collaboration equation; positive serum human chorionic gonadotropin measured at screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Non-fractionated/Dose-finding
Participants will receive a single dose of mosunetuzumab.
|
Participants will receive subcutaneous (SC) mosunetuzumab on either Day 1 or on Days 1 and 8.
Participants will receive intravenous (IV) tocilizumab as needed to manage adverse reactions.
|
Experimental: Fractionated/Dose-escalation
Participants will receive a fractionated (divided) dose of mosunetuzumab on Days 1 and 8.
|
Participants will receive subcutaneous (SC) mosunetuzumab on either Day 1 or on Days 1 and 8.
Participants will receive intravenous (IV) tocilizumab as needed to manage adverse reactions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of participants with adverse events (AEs)
Time Frame: For a minimum of 12 months after mosunetuzumab dose
|
For a minimum of 12 months after mosunetuzumab dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Serum concentration of mosunetuzumab
Time Frame: Through Month 12
|
Through Month 12
|
Peripheral B-cell count
Time Frame: Through Month 12, then every 6 months thereafter
|
Through Month 12, then every 6 months thereafter
|
Duration of B-cell depletion
Time Frame: Through Month 12, then every 6 months thereafter
|
Through Month 12, then every 6 months thereafter
|
Change from baseline in anti-drug antibodies (ADAs)
Time Frame: Through Month 12
|
Through Month 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 11, 2022
Primary Completion (Estimated)
September 25, 2024
Study Completion (Estimated)
June 1, 2025
Study Registration Dates
First Submitted
December 10, 2021
First Submitted That Met QC Criteria
December 10, 2021
First Posted (Actual)
December 13, 2021
Study Record Updates
Last Update Posted (Actual)
April 8, 2024
Last Update Submitted That Met QC Criteria
April 5, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GA43191
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org).
Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/).
For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Systemic Lupus Erythematosus
-
SanofiCompletedCutaneous Lupus Erythematosus-Systemic Lupus ErythematosusJapan
-
Kyowa Kirin Co., Ltd.RecruitingHealthy Volunteers | Systemic Lupus Erythematosus (SLE) | Cutaneous Lupus Erythematosus (CLE)Japan
-
Second Xiangya Hospital of Central South UniversityNational Natural Science Foundation of China; Hunan Provincial Natural Science... and other collaboratorsActive, not recruitingCutaneous Lupus Erythematosus | Systemic Lupus Erythematosus RashChina
-
University Hospital, BrestRecruitingSystemic Lupus Erythematosus (SLE)France
-
Beijing InnoCare Pharma Tech Co., Ltd.RecruitingSystemic Lupus Erythematosus, SLEChina
-
TJ Biopharma Co., Ltd.TerminatedSystemic Lupus Erythematosus (SLE)China
-
AstraZenecaActive, not recruitingActive Systemic Lupus ErythematosusThailand, Korea, Republic of, Philippines, China, Taiwan, Hong Kong
-
Novartis PharmaceuticalsActive, not recruitingSystemic Lupus Erythematosus (SLE)Hungary, Spain, Germany, Israel, Thailand, France, Russian Federation, China, Japan, Taiwan, Korea, Republic of, Poland, Australia, Argentina, Czechia
-
AstraZenecaPRA Health SciencesCompletedActive Systemic Lupus ErythematosusUnited States, France, Germany, Spain, Belgium, Russian Federation, Japan, Korea, Republic of, Argentina, Bulgaria, South Africa, Mexico, Canada, Brazil, Lithuania
-
Novartis PharmaceuticalsNot yet recruitingSystemic Lupus Erythematosus, SLE
Clinical Trials on Mosunetuzumab
-
Memorial Sloan Kettering Cancer CenterRecruitingLymphoma | Follicular LymphomaUnited States
-
Genentech, Inc.RecruitingNon-Hodgkin LymphomaUnited States, Puerto Rico
-
M.D. Anderson Cancer CenterGenentech, Inc.WithdrawnRefractory B-cell Acute Lymphoblastic LeukemiaUnited States
-
Weill Medical College of Cornell UniversityEpizyme, Inc.; Genentech, Inc.Recruiting
-
Washington University School of MedicineGenentech, Inc.RecruitingDiffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed B-Cell Lymphoma | Follicular Lymphoma Grade 3BUnited States
-
Hoffmann-La RocheActive, not recruitingDiffuse Large B-cell LymphomaUnited States, Israel, Spain, Korea, Republic of, Poland, Taiwan
-
Washington University School of MedicineGenentech, Inc.RecruitingB Cell Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed Lymphoma | Aggressive Lymphoma | Follicular Lymphoma Grade 3United States
-
Genentech, Inc.Active, not recruitingLymphocytic Leukemia, Chronic | Lymphoma, Non HodgkinUnited States, Korea, Republic of, Australia, United Kingdom, Germany, Canada, Spain
-
Hoffmann-La RocheActive, not recruitingB-cell Non-Hodgkin LymphomaUnited States, Canada, Belgium, Spain, United Kingdom
-
Hoffmann-La RocheRecruitingChronic Lymphocytic LeukemiaSpain, Australia, Germany, United States, Italy, United Kingdom, France